INTER PHARMA PUBLIC COMPANY LIMITEDSET: IP🇹🇭 TH

MD&A · 2025

Overview of Operations

Overview of Operations

The Company and its subsidiaries operate in the healthcare industry, focusing on the development, research, and distribution of health products for both humans and animals. In parallel, the Group has been expanding its medical and healthcare service businesses to diversify revenue streams and strengthen its long-term growth potential.

In 2025, the Company delivered significant growth in operating performance, driven by the strong performance of all core business segments. Key supporting factors included increased sales, expanded customer access channels, and strategic investments. In particular, investments and acquisitions in innovative medical device businesses and rehabilitation medicine clinics in late 2024 have strengthened the revenue base and enhanced growth opportunities.

Additionally, effective cost and expense management, along with strategic adjustments to focus on high value-added products with strong growth potential, have further supported the Company’s sustainable long-term growth.

Operating Results & Financial Condition

Operating Results & Profitability

In 2025, the Company and its subsidiaries reported improved operating performance compared to the previous year, supported by growth in sales of health products for both humans and animals, expansion of distribution channels, and the development of new products aligned with consumer health trends. As a result, the Company’s total revenue continued to increase.

For 2025, the Company recorded total revenue of approximately THB 2,214.1 million, representing an increase of THB 302 million, or 16% year-on-year. This growth was driven by higher sales across multiple product categories, as well as the expansion of domestic distribution networks.

On the cost side, the Company effectively managed its cost of goods sold and operating expenses through production cost control, supply chain optimization, and improved operational efficiency. In addition, a higher proportion of revenue from businesses with stronger gross margins, together with the consolidation of innovative medical device businesses and rehabilitation medicine clinics, contributed to an increase in the Company’s gross profit margin compared to the previous year.

In terms of profitability, the Company reported net profit of approximately THB 136.1 million in 2025, an increase of THB 99 million, or 271% year-on-year. This was primarily driven by revenue growth across all core business segments, efficient cost and expense management, and the recognition of income from newly invested businesses. Overall, the Company’s profitability has shown a positive trend, supporting continued growth.

In summary, the Company’s profitability in 2025 improved significantly. The Company remains focused on developing high value-added products, expanding healthcare-related businesses, and enhancing operational efficiency to support sustainable revenue and profit growth in the long term.

Liquidity & Capital Adequacy

In 2025, the Company and its subsidiaries experienced a significant improvement in financial liquidity. Net cash flows from operating activities were positive, reflecting a clear enhancement in the Company’s ability to generate cash from its core business operations.

With respect to investing activities, the Company managed its investments prudently in alignment with its business plans, while cash flows from financing activities were supported by careful capital structure management.

As of the end of 2025, the Company reported cash and cash equivalents of THB 280.6 million, strengthening its liquidity position and providing sufficient resources to support ongoing operations and future investment plans.

In terms of working capital management, the Company improved its efficiency in managing trade receivables by reducing the average collection period from 68 days to 61 days. The accounts receivable turnover ratio also increased from 5.37 times to 5.98 times, reflecting enhanced effectiveness in credit control and collection processes.

At the same time, the Company effectively managed its inventory, with the average inventory holding period decreasing from 81 days to 79 days. This indicates improved inventory management efficiency and contributes positively to overall liquidity.

Overall, the Company maintains a strong liquidity position and an appropriate capital structure, with operating cash flow serving as its primary funding source. This enables the Company to effectively support its operations, investments, and long-term growth.

As of the end of 2025, the Company’s cash and cash equivalents remain at a sufficient level to support normal business operations, as well as future investment and expansion plans. The Company also continuously monitors and evaluates its liquidity position to ensure its ability to meet financial obligations in a stable and sustainable manner.

In summary, the Company’s liquidity position and capital structure are sound and well-managed, enabling it to effectively support business operations, investments, and long-term growth.

Asset Management Capability

The Company has demonstrated effective asset management, with a continuous improvement trend. In the current year, the Company reported average total assets of THB 3,132.82 million, an increase from THB 2,989.70 million in the previous year, to support business expansion.

The Company generated total revenue of THB 2,214.09 million, resulting in an asset turnover ratio of 0.71 times, up from 0.64 times in the prior year. This reflects improved efficiency in utilizing assets to generate revenue.

In terms of profitability, the Company reported net profit of THB 136 million, a significant increase from the previous year. Consequently, the return on assets (ROA) improved from 1.23% to 4.34%, demonstrating a clear enhancement in the Company’s ability to generate returns from its asset base.

This improvement is attributable to enhanced operational efficiency alongside effective asset management, enabling the Company to achieve continuous growth in both revenue and profitability. In addition, the Company places strong emphasis on strategic asset management, including knowledge, technology, and product development, which are key drivers in strengthening its competitiveness in the healthcare industry.

Debt Obligations & Off-Balance-Sheet Management

In 2025, the Company and its subsidiaries managed their debt obligations prudently and appropriately. The Company structured its capital in alignment with its business operations and long-term investment plans. Its primary sources of funding include cash flows from operating activities and borrowings from financial institutions, which are used to support business operations, investment in fixed assets, and expansion into healthcare-related businesses. As a result, the Company’s debt-to-equity (D/E) ratio stood at 0.41 times, a relatively low level that reflects a strong and stable capital structure.

The Company manages its debt obligations with careful consideration of its debt servicing capacity, operating cash flows, and appropriate capital structure to maintain financial stability. It also continuously monitors its debt position and financial obligations to ensure effective debt management in line with its operational capacity. The Company’s interest coverage has improved significantly, in line with stronger operating performance and increased cash flows from operations.

Regarding off-balance sheet commitments, the Company may have obligations arising from normal business operations, such as service agreements, raw material procurement contracts, or other business arrangements. These commitments are carefully managed and monitored to ensure that they do not have a material impact on the Company’s financial position or operating results.

Overall, the Company maintains prudent management of both its debt obligations and off-balance sheet commitments under a comprehensive financial risk management framework. This enables the Company to preserve financial stability and effectively support its long-term business growth.

Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition

The Company recognizes key factors that may impact its financial position and future operating performance. It has established a systematic risk management approach to control potential impacts at an acceptable level while supporting sustainable growth. The key points are summarized as follows:

1. Growth Trends in Health and Pet Product Businesses
The health and pet product industries continue to show strong growth potential, driven by structural factors such as the aging society and the trend toward preventive healthcare, as well as the increasing humanization of pets. Although competition in the industry is expected to intensify, the Company adopts a proactive approach by closely monitoring market data and consumer behavior, developing differentiated products, and continuously strengthening its brand. This enables the Company to maintain competitiveness and effectively manage its market share.

2. Regulatory Changes and Product Registration
The Company’s products are subject to government regulations, which may involve changes in registration requirements, advertising rules, and labeling standards. The Company continuously monitors and assesses regulatory developments and ensures preparedness in terms of scientific data, internal systems, and relevant personnel to comply with applicable requirements. It also maintains close coordination with regulatory authorities. This allows the Company to efficiently manage product registration processes and regulatory compliance, minimizing the risk of delays or business disruption.

3. New Product Development and Launch
The Company focuses on continuous product development to meet market demand and support business growth, including OEM/ODM services. A structured New Product Development (NPD) process has been established, covering market research, research and development, product efficacy and safety testing, and commercial planning. This systematic approach ensures product quality, enhances the likelihood of successful market entry, and reduces earnings volatility from new product launches.

4. Risks from Market Expansion
Expanding into new markets or territories may present challenges in building brand awareness and accessing customer bases during the initial phase. The Company implements a structured market entry strategy based on in-depth market analysis, clear market positioning, appropriate channel selection, and continuous marketing activities to build brand recognition. Performance is closely monitored and evaluated.
In addition, the Company remains flexible in adjusting strategies in response to changing economic conditions and external factors, enabling effective risk management and efficient customer base development.

5. Volatility in Raw Material Costs and Exchange Rates
The Company sources certain raw materials and products from overseas, which may be affected by global price fluctuations, exchange rate movements, and international logistics factors. It has implemented prudent risk management policies, including forward procurement planning, supplier diversification to reduce dependency, negotiation of trade terms with partners, and the use of financial instruments to manage foreign exchange risks where appropriate.
At the same time, the Company closely monitors cost trends, exchange rates, and logistics conditions to adjust pricing strategies and cost management in a timely manner. This helps control impacts on profit margins and maintain operational stability effectively.

Projects or R&D Affecting Future Results

Inter Pharma Public Company Limited and its subsidiaries (“the Company”) are undertaking several significant investment and research & development (R&D) projects that are expected to materially impact the Company’s business operations, financial performance, and financial position in the near future. The key details are summarized as follows:

  1. The Company is currently implementing a project to upgrade the ophthalmic drug manufacturing standards at its Ayutthaya plant to comply with European Union (EU) standards. This project aims to enhance production capabilities and support the development of ophthalmic products at an international level. In the initial phase, the Company may incur higher expenses from capital investment, depreciation, and costs related to certification and regulatory approvals.

  2. The Company has invested in expanding the production capacity of the Modern Pharma plant, covering cosmeceutical and dietary supplement products, to support product expansion and contract manufacturing services (OEM/ODM). This investment may result in higher fixed costs and operating expenses during the initial stage, before full capacity utilization is achieved.

  3. The Company has made investments to expand its health-related businesses in order to support integrated growth across the group. Such investments may affect short-term liquidity and increase capital commitments. However, the Company expects these investments to generate commercial benefits and business synergies in the future.

  4. The Company plans to expand its distribution channels through pharmacies and has adjusted its investment structure by assigning subsidiaries to undertake such operations. This approach may help reduce part of the investment burden at the parent company level. Nevertheless, these activities will continue to impact the Company’s consolidated financial performance.

  5. The Company continues to invest in research and development of new products through its subsidiaries and/or joint ventures. While such investments may not generate revenue in the short term, they are crucial for creating business opportunities in the medium to long term. In the early stages, this may lead to increased R&D expenses.

Overall, these projects and investments may result in higher expenses and capital outlays in the short term. However, the Company expects that these initiatives will strengthen its competitive capabilities, expand its revenue base, and enhance profitability in the long run. The success of these projects depends on key factors such as product development capabilities, regulatory approvals, and competitive conditions within the industry.

Contents